209 filings
8-K
CKPT
Checkpoint Therapeutics Inc
24 Jun 24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
7:46am
S-8
CKPT
Checkpoint Therapeutics Inc
24 May 24
Registration of securities for employees
4:06pm
8-K
CKPT
Checkpoint Therapeutics Inc
14 May 24
Departure of Directors or Certain Officers
7:30am
10-Q
2024 Q1
CKPT
Checkpoint Therapeutics Inc
Quarterly report
10 May 24
4:16pm
8-K
CKPT
Checkpoint Therapeutics Inc
10 May 24
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
8:45am
EFFECT
nzbk x9i66orumqk
8 Apr 24
Notice of effectiveness
12:15am
DEFA14A
ng9c9ah ieqh76ng
2 Apr 24
Additional proxy soliciting materials
6:03am
8-K
fdzn t5fe
22 Mar 24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
8:52am
8-K
yjf8xg f4miah0g
18 Mar 24
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
4:05pm
D
n2ljoh4 uuak2e
5 Feb 24
Exempt offering of security
5:00pm
8-K
rzmu3v8m
2 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
424B5
n9156txvsb9 c2pdqb
30 Jan 24
Prospectus supplement for primary offering
5:10pm
8-K
9rcd9ldwqrv85vh
30 Jan 24
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
5:00pm
8-K
ptgy9c1 1d55
5 Jan 24
Departure of Directors or Certain Officers
5:01pm
8-K
1wjfrju80ji3b7r
18 Dec 23
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
7:10am
EFFECT
8vs219
27 Nov 23
Notice of effectiveness
12:15am